Janssen China R&D
Today, China is facing a wide array of complex and unmet medical needs: 93 million people with chronic hepatitis B , about 173 million people with a mental disorder  and 114 million with diabetes . Some 36 percent of new lung cancer patients globally are in China  and it is projected that by 2030, COPD will kill 3 million Chinese people a year .
As a global leader in human health, Janssen has an important role to play in addressing these significant medical needs and creating value through innovation in R&D and medical scien
 University of Melbourne –
 Journal of the American Medical Association,
 Wanqing, C. (2014). The epidemiology of lung cancer in China,
 Hughes, V. (2012). Public health: where there’s smoke,